Development of a public health research program for ovarian cancer

Journal of Women's Health

Volumn 15, Issue 4, 2006, Pages 339-345

  Eheman, Christie R ^a   Peipins, Lucy ^a   Wynn, Michelle ^a   Ryerson, Blythe ^a   Stewart, Sherri L ^a   Coughlin, Steven S ^a   Hawkins, Nikki A ^a   Saraiya, Mona ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CYTOREDUCTIVE SURGERY; DIAGNOSTIC APPROACH ROUTE; FEMALE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICES RESEARCH; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROCESS DEVELOPMENT; TERMINAL CARE; WORKSHOP;

FEMALE; HUMANS; MASS SCREENING; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PROGRAM DEVELOPMENT; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES; UTERINE CERVICAL NEOPLASMS; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 33745125733     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.15.339     Document Type: Article

References (35)

1. U.S. Cancer Statistics Working Group. United States cancer statistics: 2002 incidence and mortality. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2005.
2. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2002. Available at seer.cancer. gov/csr/1975_2002/
3. Buys SS, Partidge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630.
4. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, Van Nagell JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997;65:408.
5. Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992;80:14.
6. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: A prospective cohort study. BMJ 1996;313: 1355.
7. Sato S, Yokoyama Y, Sakamoto T, Futagami M, Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000;89:582.
8. U.S. Preventive Services Task Force. Screening for ovarian cancer. Rockville, MD. Agency for Healthcare Research and Quality, 2004. Available at www.ahrq.gov/clinic/uspstf/uspsovar.htm
9. van Nagell Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350.
10. Eltabbakh GH, Yadav PR, Morgan A, Yadev PR. Clinical picture of women with early stage ovarian cancer. Gynecol Oncol 1999;75:476.
11. Ferrell B, Smith S, Cullinane C, Melancon C. Symptom concerns of women with ovarian cancer. J Pain Symptom Manage 2003;25:528.
12. Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1988;27:53.
13. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000;89:2068.
14. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.
15. Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer. Obstet Gynecol 2001;98:212.
16. Smith EM, Anderson B. The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 1985;56:2727.
17. Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano P. Ovarian cancer: Can we make the clinical diagnosis earlier? Cancer 2005;104:1398.
18. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: Screening, treatment, and follow-up. JAMA 1995;273:491.
19. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Ann Intern Med 2005; 143:355.
20. Yoon PW, Scheuner MT, Khoury MJ. Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med 2003; 24:128.
21. Andersen MR, Peacock S, Nelson J, et al. Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer. Gynecol Oncol 2002;85:3.
22. Drescher C, Holt SK, Andersen MR, Anderson G, Urban N. Reported ovarian cancer screening among a population-based sample in Washington State. Obstet Gynecol 2000;96:70.
23. Miller SM, Bowen DJ, Campbell MK, et al. Current research promises and challenges in behavioral oncology: Report from the American Society of Preventive Oncology annual meeting, 2002. Cancer Epidemiol Biomarkers Prev 2004;13:171.
24. Van Nagell JR, DePriest PD. Management of adnexal masses in postmenopausal women. Am J Obstet Gynecol 2005;193:30.
25. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. Part I. A patient care evaluation study of the American College of Surgeons. Cancer 1993;71:1629.
26. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002; 84:36.
27. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203.
28. Fanning J, Gangestad A, Andrews ST. National Cancer Data Base/ Surveillance Epidemiology and End Results: Potential insensitive-measure bias. Gynecol Oncol 2000;77:450.
29. McGowan L. Patterns of care in carcinoma of the ovary. Cancer 1993;71:628.
30. Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993;72:3663.
31. Puls LE, Carrasco R, Morrow MS, Blackhurst D. Stage I ovarian carcinoma: Specialty-related differences in survival and management. South Med J 1997;90:1097.
32. Hewitt M, Simone JV. Enhancing data systems to improve the quality of cancer care. National Cancer Policy Board, Institute of Medicine, and Commission on Life Sciences, National Research Council. Washington, DC: National Academy Press, 2000.
33. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. Am J Clin Oncol 2001;19:1266.
34. Khatcheressian J, Cassel JB, Lyckholm L, Coyne P, Hagenmueller A, Smith TJ. Improving palliative and supportive care in cancer patients. Oncology 2005; 19:1365.
35. Rolnick SJ, Herrinton L, Neslund-Dudas C, Bohlke K, Hornbrook M, Coughlin S. Data collection for a pilot study of end of life care in managed care systems for women who die of ovarian cancer. Poster presentation, American Society for Preventive Oncology annual meeting, Bethesda, MD, March 14-16, 2004.